Back

Insulin resistance surpasses remnant cholesterol: the triglyceride–glucose index as a stronger predictor of coronary artery disease

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Lp(a), triglycerides and coronary artery disease Lipids ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Francisco Sousa

Hospital Central do Funchal, Funchal (Portugal)

5 More presentations in this session

Presentation thumbnail
Sex-specific differences in lipoprotein (a) levels and their shared impact on coronary artery disease extent in ACS
Doctor F. Buendia Santiago (Cartagena, ES)
Abstract Slides
Presentation thumbnail
Cumulative LDL-cholesterol exposure after Index percutaneous coronary intervention and subsequent major adverse cardiac and cerebrovascular events
Doctor S. KAGEYAMA (Shizuoka, JP)
Abstract Slides
Presentation thumbnail
Transient surge, persistent risk: longitudinal changes in lipoprotein(a) following acute coronary syndrome
Doctor K. Mahajan (Mandi, IN)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) adds no predictive value for coronary disease beyond traditional risk factors
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Remnant cholesterol: an independent determinant of coronary artery disease and future cardiovascular events beyond traditional risk factors
Doctor F. Sousa (Funchal, PT)
Abstract Slides

Access the full session

Session thumbnail
Lp(a), triglycerides and coronary artery disease

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Triglycerides glucose index and high-sensitivity C-reactive protein are predictors of outcome in chronic coronary syndrome
9 May 2021
thumbnail
Congress Presentation
Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apolipoprotein B: a cohort study
1 September 2024
thumbnail
Congress Presentation
Impact of calculated LDL-c on residual cardiovascular risk assessment
23 April 2026
thumbnail
Congress Presentation
Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with valsartan/amlodipine in prediabetic patients
7 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources